An exploratory, double blind, randomized, placebo-controlled, 2-way cross-over study to assess the effect of repeat-dose inhaled indacaterol maleate [indacaterol] (300 mcg) on dynamic and static lung hyperinflation, subjective breathlessness and health status in patients with COPD

Trial Profile

An exploratory, double blind, randomized, placebo-controlled, 2-way cross-over study to assess the effect of repeat-dose inhaled indacaterol maleate [indacaterol] (300 mcg) on dynamic and static lung hyperinflation, subjective breathlessness and health status in patients with COPD

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2012

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 30 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-004684-22).
    • 29 Aug 2011 Trial phase changed from III to II as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top